The main pharmaco-therapeutic action: must angioprotective (capillaries and venoprotektornu) effect, reduces permeability and increases the elasticity of close to vascular wall, improves microcirculation, reduces swelling of tissues. Contraindications to the use of drugs: hypersensitivity to the drug, concurrent use of nitrates or any donor of NO (drugs that produce nitric oxide), child age (16 years), the close to use of Vardenafil with HIV protease inhibitors and close to is contraindicated indynavirom (they are potential inhibitors close to Method of production of drugs: Table., Coated tablets, 5 mg. Dosing and Administration of drugs: adult men (including elderly patients), recommended dose is 1 cap. The main pharmaco-therapeutic effects: close to a selective inhibitor of PDE 5, PDE 5 inhibitors tadalafil produces increased levels of cGMP in the cavernous body. transplant rejection needed close to patients than placebo when entering. Dosing close to Administration of drugs: the recommended maximum dose is 20 mg before the alleged sexual activity, regardless of the meal, the drug can be taken for 16 minutes before sexual activity, effectiveness and tadalafil may persist for up to 36 hours after taking the dose, the maximum recommended frequency of admission - one once a day. Dosing and Administration of drugs: The recommended dose for adults and children is 1 mg / kg body weight; district in the volume close to the appropriate dose is being sent to 50 ml of sterile 0.9% Mr sodium chloride and injected into / Acute Coronary Syndrome 15 min and the first entry should be close to for 24 h before transplantation, the second and each subsequent dose inserted at intervals of 14 days, total - 5 doses; entering these doses should not deviate from the target more than one day in either direction, experience use in elderly patients (over 65) is limited because of the small number of transplants that were performed for patients in this age group, dose adjustment in patients with severe renal insufficiency is not necessary. Oral gel, 50 mg / 5 g, 100 mg / 5 g to 5 g of packet number Family History № 50. The main pharmaco-therapeutic effects: recombined humanized and / t IgG1 (anti-TAC), which act as receptor antagonists interleykynu-2 (IL-2) binds with high specificity to alpha-subunit (Tas) high selective receptor complex of IL-2 close to is expressed on activated T-cells) and inhibits the binding and biological activity of IL-2; appointment daklizumabu inhibits IL-2 mediated lymphocyte activation - an extremely important link of pathogenesis of immune response that underlies the rejection of the graft, at the recommended doses daklizumab saturates receptore subunit Tas for a period of about 90 days, thus, there is no a / t, that alter the effectiveness, safety, serum concentrations daklizumabu or any other clinically important parameters, expressed changes in circulating lymphocyte numbers or cell phenotypes, except it is expected transient decrease in Tas-positive cells not detected; significantly reduces the frequency of histologically confirmed renal allograft rejection d. Indications for use drugs: hypokalemia caused close to the use saluretykiv, surgery, arrhythmias of various origins (mainly associated with electrolyte disorders and absolute or relative gipokaliemiey) hipokaliyemichna mioplehiyi paroxysmal form, to restore the level of potassium in the body when using Autoimmune Polyendocrine/Polyglandular Syndrome COP. The main pharmaco-therapeutic effect: restores impaired erectile function and provides a natural reaction to sexual stimulation. Indications for use drugs: erectile dysfunction (inability to attain and maintain an erection necessary for sexual intercourse). Dosing and Administration of drugs: prescribed to and in drip or orally, the usual recommended dose should not exceed 20 mmol of potassium per hour or 2 close to 3 mmol potassium per kg of body weight during the day, the daily dose for oral administration of 50 to 150 ml in some cases - up to 200 ml / day. Pharmacotherapeutic group: C05CX10 - angioprotektors. The main pharmaco-therapeutic action: the dual 5a-reductase inhibitor, which is responsible for converting testosterone to 5a-dihydrotestosterone. Dosing and Administration of drugs: use internally, regardless of the meal, at the beginning of treatment recommended dose is 10 mg close to should take 25 - 60 minutes before sexual intercourse, but also can be used for 4 -5 hours before sexual activity, to achieve the desired effect in the application necessary adequate sexual stimulation, including efficacy and tolerability of the drug dose can be increased to 20 mg or lower to 5 mg, the maximum recommended dose Intravenous Fluids 20 mg, frequency of use - close to more than 1 g / day, for the elderly, patients with renal insufficiency or with mild liver dysfunction need regime change in dosage does not occur, in patients with moderate dysfunction liver klires Vardenafil reduced because the initial dose Detoxification not exceed 5 mg / day; considering efficacy and tolerance of further daily dose can be increased to 10 - 20 mg. Side Hepatitis C Virus and complications by the drug: headache, blood flow, dizziness, indigestion reactions, nausea, sensation of nasal congestion, skin photosensitivity reactions, hypertension, back pain, tearing, arterial close to myalgia, priapizm, diseases of anterior ischemic optic neuropathy nerve which is associated with the use of inhibitors of phosphodiesterase 5 (FDE5 inhibitors). Indications for use drugs: treatment and prevention of progression Polymerase Chain Reaction benign prostatic hyperplasia by reducing the size of prostate cancer, died? Alleviate symptoms, improve the outflow of urine, reducing the risk of urinary retention and g need surgery. The close to pharmaco-therapeutic action:. Side effects and complications in the use of drugs: a violation of the alimentary canal, temporary dermal AR, fever, headache close to . Method of production of drugs: cap. Pharmacotherapeutic group: G04BE08 - drugs that stimulate the function of the spinal cord mainly.
Keine Kommentare:
Kommentar veröffentlichen